Nuvation Bio Inc. (NYSE:NUVB - Get Free Report)'s stock price hit a new 52-week low on Thursday. The company traded as low as $3.73 and last traded at $3.8850, with a volume of 564,977 shares trading hands. The stock had previously closed at $3.78.
Wall Street Analysts Forecast Growth
NUVB has been the topic of a number of analyst reports. JPMorgan Chase & Co. started coverage on Nuvation Bio in a research note on Tuesday, August 18th. They set an "overweight" rating and a $13.00 price objective for the company. Citizens Jmp restated a "market outperform" rating and issued a $10.00 target price on shares of Nuvation Bio in a research note on Wednesday, September 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Nuvation Bio in a research note on Thursday, October 15th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Nuvation Bio in a report on Wednesday, September 16th. Finally, HC Wainwright reiterated a "buy" rating and set a $21.00 target price on shares of Nuvation Bio in a research report on Tuesday. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $13.00.
Check Out Our Latest Stock Report on Nuvation Bio
Nuvation Bio Trading Up 4.4%
The company has a 50-day simple moving average of $4.96 and a 200-day simple moving average of $5.31. The company has a debt-to-equity ratio of 1.23, a quick ratio of 7.30 and a current ratio of 7.45. The stock has a market cap of $1.39 billion, a P/E ratio of -9.86 and a beta of 1.73.
Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The company had revenue of $44.95 million for the quarter, compared to analyst estimates of $34.39 million. Nuvation Bio had a negative return on equity of 45.69% and a negative net margin of 67.38%. On average, sell-side analysts forecast that Nuvation Bio Inc. will post -0.37 EPS for the current fiscal year.
Institutional Investors Weigh In On Nuvation Bio
Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its stake in shares of Nuvation Bio by 136.9% in the third quarter. Goldman Sachs Group Inc. now owns 4,511,958 shares of the company's stock worth $25,267,000 after acquiring an additional 2,607,272 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Nuvation Bio by 19.7% during the third quarter. First Trust Advisors LP now owns 1,558,880 shares of the company's stock worth $8,730,000 after purchasing an additional 256,543 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of Nuvation Bio by 19.5% during the second quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company's stock valued at $6,996,000 after purchasing an additional 200,621 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Nuvation Bio by 75.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company's stock valued at $6,175,000 after purchasing an additional 619,725 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Nuvation Bio by 6.5% during the second quarter. Wellington Management Group LLP now owns 715,781 shares of the company's stock valued at $4,066,000 after purchasing an additional 43,637 shares during the last quarter. Institutional investors own 61.67% of the company's stock.
Nuvation Bio Company Profile
(
Get Free Report)
Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.